Patrick Engelberts

1.3k total citations
18 papers, 880 citations indexed

About

Patrick Engelberts is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Patrick Engelberts has authored 18 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Oncology and 7 papers in Immunology. Recurrent topics in Patrick Engelberts's work include Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Patrick Engelberts is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Patrick Engelberts collaborates with scholars based in Netherlands, United States and Denmark. Patrick Engelberts's co-authors include Paul W.H.I. Parren, Frank J. Beurskens, Ronald P. Taylor, Janine Schuurman, Margaret A. Lindorfer, Paul V. Beum, Aran F. Labrijn, Esther C.W. Breij, Bruce A. Braaten and David A. Low and has published in prestigious journals such as Blood, Molecular Cell and The Journal of Immunology.

In The Last Decade

Patrick Engelberts

17 papers receiving 862 citations

Peers

Patrick Engelberts
Jantine E. Bakema Netherlands
Steven L. Giardina United States
Jalal Khoshnoodi Iran
Paul Sims United States
Bent Rubin France
Fabrice Le Gall Germany
Irene Ni United States
Maaike Nederend Netherlands
N M Avdalovic United States
Lukas A. Oomen Netherlands
Jantine E. Bakema Netherlands
Patrick Engelberts
Citations per year, relative to Patrick Engelberts Patrick Engelberts (= 1×) peers Jantine E. Bakema

Countries citing papers authored by Patrick Engelberts

Since Specialization
Citations

This map shows the geographic impact of Patrick Engelberts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Engelberts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Engelberts more than expected).

Fields of papers citing papers by Patrick Engelberts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Engelberts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Engelberts. The network helps show where Patrick Engelberts may publish in the future.

Co-authorship network of co-authors of Patrick Engelberts

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Engelberts. A scholar is included among the top collaborators of Patrick Engelberts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Engelberts. Patrick Engelberts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Engelberts, Patrick, et al.. (2024). CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing. Communications Biology. 7(1). 983–983. 5 indexed citations
3.
Kemper, Kristel, Péter Boross, Mischa Houtkamp, et al.. (2022). Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life Science Alliance. 5(11). e202201481–e202201481. 3 indexed citations
4.
Oostindie, Simone C., Mir Farshid Alemdehy, Maarten L. Janmaat, et al.. (2022). Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies. Blood. 140(Supplement 1). 3153–3154. 6 indexed citations
5.
Middelburg, Jim, Kristel Kemper, Patrick Engelberts, et al.. (2021). Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers. 13(2). 287–287. 99 indexed citations
6.
Engelberts, Patrick, Ida H. Hiemstra, Danita H. Schuurhuis, et al.. (2020). DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 52. 102625–102625. 102 indexed citations
7.
Hiemstra, Ida H., Patrick Engelberts, Danita H. Schuurhuis, et al.. (2019). PS1301 POTENT ANTI‐TUMOR ACTIVITY OF DUOBODY®‐CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO. HemaSphere. 3(S1). 594–594. 1 indexed citations
8.
Hiemstra, Ida H., Patrick Engelberts, Danita H. Schuurhuis, et al.. (2018). Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies. Blood. 132(Supplement 1). 1664–1664. 2 indexed citations
9.
Jong, Rob N. de, Frank J. Beurskens, Sandra Verploegen, et al.. (2016). A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biology. 14(1). e1002344–e1002344. 153 indexed citations
10.
Engelberts, Patrick, Marleen Voorhorst, Janine Schuurman, et al.. (2016). Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. The Journal of Immunology. 197(12). 4829–4837. 32 indexed citations
11.
Beurskens, Frank J., Marleen Voorhorst, Patrick Engelberts, et al.. (2015). Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. mAbs. 7(4). 672–680. 51 indexed citations
12.
Engelberts, Patrick, Ronald P. Taylor, Esther C.W. Breij, et al.. (2014). Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 100(1). 77–86. 120 indexed citations
13.
14.
Beurskens, Frank J., Margaret A. Lindorfer, Mohammed Farooqui, et al.. (2012). Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. The Journal of Immunology. 188(7). 3532–3541. 96 indexed citations
15.
Beum, Paul V., Margaret A. Lindorfer, Frank J. Beurskens, et al.. (2011). Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells. The Journal of Immunology. 187(6). 3438–3447. 104 indexed citations
16.
Hernday, Aaron D., Bruce A. Braaten, Gina Broitman-Maduro, Patrick Engelberts, & David A. Low. (2004). Regulation of the Pap Epigenetic Switch by CpxAR. Molecular Cell. 16(4). 537–547. 70 indexed citations
17.
Hernday, Aaron D., Bruce A. Braaten, Gina Broitman-Maduro, Patrick Engelberts, & David A. Low. (2004). Regulation of the Pap Epigenetic Switch by CpxARPhosphorylated CpxR Inhibits Transition to the Phase ON State by Competition with Lrp. Molecular Cell. 16(4). 537–547. 24 indexed citations
18.
Blitterswijk, Clemens van, et al.. (2003). Studying the Effect of Different Macrostructures on in vitro Cell Behaviour and in vivo Bone Formation Using a Tissue Engineering Approach. Novartis Foundation symposium. 249. 148–169. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jantine E. Bakema Breakdown of academic impact, for papers by Steven L. Giardina Breakdown of academic impact, for papers by Jalal Khoshnoodi Breakdown of academic impact, for papers by Paul Sims Breakdown of academic impact, for papers by Bent Rubin Breakdown of academic impact, for papers by Fabrice Le Gall Breakdown of academic impact, for papers by Irene Ni Breakdown of academic impact, for papers by Maaike Nederend Breakdown of academic impact, for papers by N M Avdalovic Breakdown of academic impact, for papers by Lukas A. Oomen
Rankless by CCL
2026